Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: KMT2A(11q23)-rearranged acute myeloid leukemia (KMT2A-r AML) represents a clinically aggressive subtype with heterogeneous outcomes. Current evidence remains inconclusive regarding the prognostic relevance of fusion partners in 11q23/KMT2A-rearranged AML. The comprehensive mutational landscape and prognostic implications of co-occurring driver mutations remain poorly characterized.
Methods: A comprehensive clinicogenomic analysis of 159 de novo KMT2A-r AML patients was conducted to assess the correlation between molecular profiles and clinical outcomes.
Results: Notably, the KMT2A::MLLT4 subgroup exhibited significantly higher KRAS mutation frequencies compared to other rearrangement groups (p < .05). Survival analysis revealed that the KMT2A::MLLT4 cohort demonstrated trends toward inferior overall survival (OS) and increased cumulative incidence of relapse (CIR) relative to other rearrangement subgroups. Stratified by mutational status, patients with KRAS mutations exhibited significantly inferior 2-year OS rates (24.6% vs. 50.5%; p = .001) and higher 2-year CIR (56.3% vs. 34.6%; p = .018) compared to KRAS wild-type counterparts. This adverse prognostic association remained in the transplanted cohort (OS: 32.3% vs. 73.5%; p < .001; CIR: 73.6% vs. 23.0%; p < .001). In contrast, mutations in NRAS, FLT3 did not demonstrate statistically significant associations with OS or CIR in either the overall cohort or transplant subgroup. Multivariable Cox regression confirmed KRAS mutation as an independent adverse prognostic factor for both 2-year OS (hazard ratio [HR], 0.51; 95% CI, 0.31-0.84; p = .008) and CIR (HR, 1.80; 95% CI, 1.04-3.12; p = .037) in the overall cohort. This association persisted in the transplanted patients subgroup (OS: HR, 0.18; 95% CI, 0.06-0.52; p = .001; CIR: HR, 3.89; 95% CI, 1.05-14.37; p = .042).
Conclusions: These results demonstrate the independent prognostic value of KRAS mutations across treatment modalities, including both conventional chemotherapy and hematopoietic stem cell transplantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.35941 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
KRAS mutations in Non-Small Cell Lung Cancer: translational aspects, current therapies and challenges for future research.
Crit Rev Oncol Hematol
September 2025
Unit of Cancer Genetics, Institute of Genetic & Biomedical Research (IRGB), National Research Council (CNR), Traversa La Crucca n. 3, 07100, Sassari, Italy; Immuno-Oncology & Targeted Cancer Biotherapies, University of Sassari, Viale San Pietro 43, 07100, Sassari, Italy. Electronic address: gpalmier
Mutations in the KRAS gene are prominent oncogenic drivers in non-small cell lung cancer (NSCLC), with multiple pathophysiological, clinical and prognostic implications. Although historically considered an "undruggable" target, recent research led to the development of specific KRAS-G12C inhibitors, like sotorasib and adagrasib which are currently approved for clinical use in patients affected by advanced NSCLC. However, the clinical utility of these drugs is often limited by resistance development through several biological mechanisms, including additional KRAS mutations, activation of compensatory pathways and metabolic reprogramming.
View Article and Find Full Text PDFIdentifying meaningful drug response biomarkers from public pharmacogenomic datasets with biologically informed interpretable neural networks.
Comput Biol Chem
September 2025
Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macao Special Administrative Region of China. Electronic address:
With the advancements of next-generation sequencing, publicly available pharmacogenomic datasets from cancer cell lines provide a handle for developing predictive models of drug responses and identifying associated biomarkers. However, many currently available predictive models are often just used as black boxes, lacking meaningful biological interpretations. In this study, we made use of open-source drug response data from cancer cell lines, in conjunction with KEGG pathway information, to develop sparse neural networks, K-net, enabling the prediction of drug response in EGFR signaling pathways and the identification of key biomarkers.
View Article and Find Full Text PDFComprehensive analysis of oncogenic determinants across tumor types via multi-omics integration.
Cancer Genet
August 2025
National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India. Electronic address:
Cancer is a complex and heterogeneous disease characterized by the accumulation of genetic and epigenetic alterations that drive uncontrolled cellular proliferation and survival. This review provides a comprehensive overview of key cancer driver genes, including oncogenes such as KRAS and PIK3CA, as well as tumor suppressor genes like TP53, PTEN, and CDKN2A, highlighting their molecular mechanisms and roles across various types of cancer. Leveraging insights from large-scale cancer genome initiatives and whole-genome sequencing, we examine the landscape of somatic mutations and their association with hallmark cancer pathways, including cell cycle regulation, apoptosis, metabolic reprogramming, and immune evasion.
View Article and Find Full Text PDFPlasma cfDNA analysis of alectinib resistance-related gene alterations in the J-ALEX study.
ESMO Open
September 2025
Department of Medical Oncology, Kanazawa University Hospital, Kanazawa, Japan. Electronic address:
Background: Resistance to alectinib, the standard first-line therapy for anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC), remains a major clinical challenge. This study aimed to investigate resistance mechanisms using next-generation sequencing (NGS) of plasma cell-free DNA (cfDNA).
Materials And Methods: Plasma samples from 67 patients in the alectinib group of the J-ALEX study were collected at baseline, on day 57, and at treatment discontinuation.
First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap.
Immunotherapy
September 2025
Department of Medical Oncology, Fortrea Inc., Durham, NC, USA.
Introduction: Pembrolizumab is a standard first-line therapy for advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking actionable mutations. Data from lower-middle-income countries (LMICs) remain scarce.
Methods: From January 2019 to June 2024, we prospectively analyzed 78 a/mNSCLC patients receiving pembrolizumab-based first-line therapy.